

# Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

Robert A Adler,<sup>1\*</sup> Ghada El-Hajj Fuleihan,<sup>2\*</sup> Douglas C Bauer,<sup>3</sup> Pauline M Camacho,<sup>4</sup> Bart L Clarke,<sup>5</sup> Gregory A Clines,<sup>6</sup> Juliet E Compston,<sup>7</sup> Matthew T Drake,<sup>5</sup> Beatrice J Edwards,<sup>8</sup> Murray J Favus,<sup>9</sup> Susan L Greenspan,<sup>10</sup> Ross McKinney Jr,<sup>11</sup> Robert J Pignolo,<sup>12</sup> and Deborah E Sellmeyer<sup>13</sup>

<sup>1</sup>McGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine, Richmond, VA, USA

<sup>2</sup>American University of Beirut Medical Center, Beirut, Lebanon

<sup>3</sup>University of California, San Francisco, San Francisco, CA, USA

<sup>4</sup>Loyola University of Chicago, Maywood, IL, USA

<sup>5</sup>Mayo Clinic College of Medicine, Rochester, MN, USA

<sup>6</sup>University of Michigan, Ann Arbor, MI, USA

<sup>7</sup>University of Cambridge School of Clinical Medicine, Cambridge, UK

<sup>8</sup>MD Anderson Cancer Center, Houston, TX, USA

<sup>9</sup>University of Chicago, Chicago, IL, USA

<sup>10</sup>University of Pittsburgh, Pittsburgh, PA, USA

<sup>11</sup>Duke University School of Medicine, Durham, NC, USA

<sup>12</sup>University of Pennsylvania, Philadelphia, PA, USA

<sup>13</sup>The Johns Hopkins Bayview Medical Center, Baltimore, MD, USA

## ABSTRACT

Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than those switched to placebo after 5 years. In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures compared with those switched to placebo after 3 years. Low hip *T*-score, between  $-2$  and  $-2.5$  in FLEX and below  $-2.5$  in HORIZON extension, predicted a beneficial response to continued therapy. Hence, the Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered. In women at high risk, for example, older women, those with a low hip *T*-score or high fracture risk score, those with previous major osteoporotic fracture, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be considered. The risk of atypical femoral fracture, but not osteonecrosis of the jaw, clearly increases with BP therapy duration, but such rare events are outweighed by vertebral fracture risk reduction in high-risk patients. For women not at high fracture risk after 3 to 5 years of BP treatment, a drug holiday of 2 to 3 years can be considered. The suggested approach for long-term BP use is based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women, and does not replace the need for clinical judgment. It may be applicable to men and patients with glucocorticoid-induced osteoporosis, with some adaptations. It is unlikely that future trials will provide data for formulating definitive recommendations. © 2015 American Society for Bone and Mineral Research.

**KEY WORDS:** BISPHOSPHONATES; LONG TERM-BISPHOSPHONATE USE; RISK BENEFIT; DRUG HOLIDAY; OTHER OSTEOPOROSIS THERAPIES

## Introduction

A fracture owing to osteoporosis occurs every 3 seconds around the world, with the hallmark fractures at the spine and hip leading to substantial mortality, morbidity, and huge

societal costs worldwide.<sup>(1,2)</sup> One in three older women and one in five older men will experience a fragility fracture<sup>(2)</sup> after age 50 years. Solid evidence from randomized placebo-controlled trials of 3 to 4 years' duration supports the efficacy of amino-bisphosphonates (BPs) in decreasing the risk of vertebral

Received in original form February 20, 2015; revised form September 4, 2015; accepted September 7, 2015. Accepted manuscript online September 9, 2015.

Address correspondence to: Robert A. Adler, M D. E-mail: Robert.Adler@va.gov; Ghada El-Hajj Fuleihan, M D., MPH. E-mail: gf01@aub.edu.lb

\*RAA and GE-HF are co-chairs of the Task Force and co-primary authors.

Additional Supporting Information may be found in the online version of this article.

Journal of Bone and Mineral Research, Vol. 31, No. 1, January 2016, pp 16–35

DOI: 10.1002/jbmr.2708

© 2015 American Society for Bone and Mineral Research

fractures (by 40% to 70%), hip fractures (by 20% to 50%), and nonvertebral fractures (by 15% to 39%), depending on the drug, skeletal site, and individual risk profile. These drugs have, therefore, dominated the landscape of osteoporosis therapies for the last two decades. They are approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of postmenopausal, glucocorticoid-induced, and male osteoporosis. Between 2005 and 2009, approximately 150 million prescriptions were dispensed in the United States (US) for the oral BPs alendronate (ALN), risedronate (RIS), or ibandronate (IBN), and 5.1 million patients over the age of 55 years received a prescription for these drugs in 2008.<sup>(3)</sup> Extension trials have suggested efficacy of prolonged BP therapy in maintaining bone density for up to 10 years with ALN,<sup>(4,5)</sup> 7 years with RIS,<sup>(6)</sup> and 6 years with zoledronic acid (ZOL),<sup>(7)</sup> but evidence regarding fracture risk reduction with prolonged therapy is less convincing.

However, less than a decade after the publication of the first pivotal clinical trial with ALN in 1995, reports regarding serious complications, potentially related to the cumulative intake of such drugs, began to appear in the literature. The most alarming to dentists and patients are osteonecrosis of the jaw (ONJ), first reported by dentists and oral surgeons in 2003, occurring much more commonly in cancer patients receiving higher cumulative doses of BPs than in patients with osteoporosis treated with lower doses, and atypical femoral fractures (AFFs), first reported in 2005. Many subsequent publications have appeared on both conditions, including three major reports from American Society for Bone and Mineral Research (ASBMR) Task Forces.<sup>(8–10)</sup> Although ONJ was first described more than 160 years ago, its association with the intake of BPs was new, and it was observed to occur more commonly in the setting of cancer treatment in which high doses of intravenous BPs are used. AFFs can occur in patients not receiving any antifracture medications; they account for about 1% of all femoral fractures<sup>(11,12)</sup> and about 3% of all femoral shaft fractures.<sup>(13)</sup> The incidence of AFFs seems to increase in patients taking long-term BPs for osteoporosis. This led the FDA to request information from all BP drug manufacturers regarding this potential safety signal and to assess long-term efficacy.<sup>(14)</sup> On October 13, 2010, the FDA reviewed all available data, including data summarized in the ASBMR Task Force initial report on Atypical Subtrochanteric and Diaphyseal Femoral Fractures,<sup>(10)</sup> and determined that new “Warnings and Precautions” information regarding the risk of AFFs should be added to the labels of all BP products approved for the prevention or treatment of osteoporosis. In September 2011, the FDA held a hearing to review the long-term safety and efficacy of BPs, and subsequently recommended that physicians reassess the indication for continued BP therapy beyond 3 to 5 years,<sup>(14,15)</sup> but noted that in high-risk patients, drug discontinuation may not be advisable. Currently, all FDA approvals of BPs for the treatment of osteoporosis contain the following “Important Limitation of Use” statement: “The optimal duration of use has not been determined. All patients on BP therapy should have the need for continued therapy re-evaluated on a periodic basis.”<sup>(16)</sup>

With additional reports, the association between BPs and AFFs has become more compelling. In its second report on Atypical Subtrochanteric and Diaphyseal Femoral Fractures,<sup>(9)</sup> the ASBMR Task Force revised the original case definition of AFFs, summarized the updated relevant literature, and underscored the significant association with BP use, although with differing strengths and magnitude. Although the relative risk for BP use

varied widely (between 2- and 128-fold), the absolute risk was consistently low, ranging between 3.2 to 50 cases/100,000 person-years, an estimate that appeared to double with prolonged duration of BP use (>3 years, median duration 7 years), and seemed to decline with discontinuation. The incidence of ONJ in patients with osteoporosis is estimated to be between 1/10,000 and 1/100,000, and is only slightly higher than the ONJ incidence in the general population.<sup>(8,17)</sup> Collectively, however, these rare yet serious harmful events have received wide coverage in the media and have resulted in perceived risks by the public that may be out of proportion to the absolute risks, leading patients to not fill or refill prescriptions for these drugs. Such behavior is likely to result in fractures that could have been prevented, given that patients need to take at least 75% of doses in order to prevent fractures.<sup>(18)</sup>

The persistent effect of BPs on bone, albeit with differing temporal resolution upon discontinuation because of differential avidity to bone,<sup>(19)</sup> coupled with concerns regarding perceived harms from such therapy, led to the concept of a drug holiday. The drug holiday is designed to minimize side effects and maximize benefits and is an approach that has been successfully applied in other chronic disease states, such as rheumatoid arthritis and Parkinson’s disease.<sup>(20,21)</sup> Organizations have provided guidance regarding the risks and benefit of BP drug holidays in individuals who have received BPs for 3 to 5 years. The American Association of Clinical Endocrinologists (ACE) guideline suggests a drug holiday after 4 to 5 years of BP treatment in patients at moderate risk of fractures and after 10 years for high-risk patients, but the terms high and moderate risk were not defined.<sup>(22)</sup> The National Osteoporosis Guideline Group (NOGG) in the UK developed a care path algorithm that suggests a drug holiday in individuals who have no history of fracture, whose FRAX risk falls below the NOGG intervention threshold, and whose hip bone mineral density (BMD) *T*-score is above  $-2.5$ ; in such patients, repeating FRAX with BMD in 1.5 to 3 years was recommended.<sup>(23)</sup>

In 2013, in response to increasing concerns about prolonged BP therapy in osteoporosis patients, ASBMR leadership convened a multidisciplinary international task force on Managing Osteoporosis Patients after Long-Term Bisphosphonate Treatment. Experts in osteoporosis management, epidemiology, endocrinology, geriatrics, and drug surveillance were appointed to the Task Force. A bone scientist not in the osteoporosis field and an ethicist were also members of the Task Force. Task Force members were vetted by the ASBMR Ethics Committee and approved by the ASBMR Executive Committee.<sup>(24)</sup> Task Force member conflicts of interest are listed in the Disclosures section.

## Charges to the Task Force

The main charges were determined by the ASBMR Professional Practice Committee, approved by Council, and subsequently modified by Task Force members to follow complementary themes and facilitate work amongst members. These were to:

- Provide guidance on duration of BP therapy in patients with postmenopausal osteoporosis, developing an algorithm that incorporates risk assessment (efficacy).
- Determine how potential harms may affect duration of therapy (safety), with a risk/benefit perspective.
- Discuss how the algorithm may apply to men and to individuals with glucocorticoid-induced osteoporosis.

Additional relevant points, namely risk factors for harms, resolution of benefits and harms upon BP discontinuation, monitoring on and off therapy, differential effects and costs of BPs, and alternative therapies, were also to be reviewed. In light of the limited evidence available, the task force developed a suggested approach, rather than an algorithm. Case studies were also included to illustrate the applicability of the suggested approach to challenging clinical cases, where available evidence falls short of providing strong guidance and recommendations, and are discussed in Supplemental Appendix S1.

Details regarding the original and modified charges can be found in Supplemental Appendix S2.

## Materials and Methods

### Methodology for the literature search

Three parallel systematic literature searches were implemented on the following terms: randomized controlled trials with long-term bisphosphonates, bisphosphonates and drug holidays, and bisphosphonates and guidelines. The databases searched included Ovid Medline, EmBASE, Cochrane, and PubMed. The three searches were constructed, conducted with input and oversight from an expert medical librarian, and implemented by a research assistant at the American University of Beirut under supervision of one of the Task Force co-chairs (GE-HF). A detailed description of the search strategy and its yield is found in Supplemental Appendix 3.

### Task Force process

The Task Force met by multiple teleconferences and emails, in addition to two face-to-face meetings. Two subgroups were formed, one charged with assessing BP effectiveness over time and the other BP safety. By consensus, the first subgroup constructed a figure illustrating the essential findings and recommendations of the Task Force. The second subgroup addressed side effects of BP therapy, constructing a figure relating the probability of serious adverse outcomes with osteoporotic fracture risk and other serious life events. It also reviewed risks of alternative therapies to BPs. The Task Force co-chairs wrote the first and subsequent drafts of the manuscript with input from all members, who provided sections to address specific questions raised during the teleconferences. The figure and text underwent multiple revisions based on e-mails and discussions and were circulated to all Task Force members. The entire Task Force unanimously approved the final report.

## Evidence for Long-Term BP Treatment of Osteoporosis Extension Studies Using BPs

Pivotal registration trials have unequivocally demonstrated the antifracture efficacy of commonly used BPs, namely ALN, RIS, ZOL, and IBN.<sup>(6,25–31)</sup> Fracture reduction for vertebral, non-vertebral, and hip fractures has been established for the first three, and hip fracture was a primary outcome only for the RIS and ZOL trials.<sup>(26,30)</sup> The long-term efficacy of these BPs in extension studies is primarily based on trials conducted in a subset of trial participants and focused primarily on bone density changes. In these studies, subjects were rerandomized (after a 1- to 2-year period of open-label ALN in FLEX), and fracture reduction was evaluated as an exploratory outcome. IBN


was not studied beyond 5 years,<sup>(32)</sup> and the extension study for RIS had no placebo group and only included a small number of subjects followed for up to 7 years ( $N = 74$ ).<sup>(6)</sup> Additional details on currently used BPs are provided under the section below entitled “Differences among bisphosphonates.” Therefore, evidence supporting long-term BP therapy beyond 5 years is derived from two randomized, double-blind discontinuation trials conducted in the US and Europe, with ALN (FLEX study) and ZOL (HORIZON extension study).

The FLEX study was an extension of the ALN Fracture Intervention Trial (FIT), including both of its substudies, the Vertebral Fracture Arm<sup>(25)</sup> and the Clinical Fracture Arm.<sup>(33)</sup> The extension study randomized 1099 postmenopausal women who had already received 4 to 5 years of oral ALN, 5 to 10 mg/d, including up to 1 year open-label ALN (10 mg/d), to either continue ALN 5 mg ( $n = 321$ ), 10 mg ( $n = 322$ ), or switch to placebo ( $n = 428$ ),<sup>(4,34)</sup> (Supplemental Appendix S4A-McNabb 2013 Fig. 1 for study flow). All women also received 500 mg of calcium and 250 IU of vitamin D3 daily.

At entry into the extension study, the mean age was 73 ( $\pm 5.7$ ) years, and more than 96% were white. The mean total hip  $T$ -score was  $-1.9$  and the mean femoral neck  $T$ -score was  $-2.2$ . Importantly, women with a total hip BMD  $T$ -score  $< -3.5$  or whose total hip BMD was lower than at FIT baseline were excluded from the extension. Sixty percent of women had a history of clinical fracture after age 45 years, and one-third had already suffered a vertebral fracture. The primary endpoint was the change in femoral neck BMD; secondary measures were BMD at other sites and bone turnover markers. Fracture incidence was an exploratory objective, captured as adjudicated vertebral and nonvertebral fractures, as done in FIT. Morphometric vertebral fractures were ascertained through lateral radiographs, obtained at entry and after 36 and 60 months of the extension. A semiquantitative method was used, and mild fractures (20% height loss) were included.

After an additional 5 years of follow-up, those who continued on ALN (5 or 10 mg,  $N = 662$ ) had significantly less bone loss at all skeletal sites (for example, femoral neck BMD change by dual-energy X-ray absorptiometry (DXA) was 0.46% in combined ALN versus  $-1.48\%$  in placebo,  $p < 0.001$ ), and fewer clinical vertebral fractures (RR = 0.45, 95% confidence interval [CI] 0.24–0.85) compared with those who were switched to placebo,  $N = 437$ <sup>(4)</sup> (see Supplemental Appendix S4A, Black 2006, Table 3). However, nonspine fracture risk was similar among those who continued ALN for approximately 10 years compared with women who received 5 years of ALN followed by 5 years of placebo (RR = 1.00, 95% CI 0.76–1.32), but the study did not have adequate statistical power to detect differences in nonvertebral fractures. There was no significant reduction in morphometric vertebral fractures with continued therapy beyond 5 years (RR = 0.86, 95% CI 0.60–1.22).<sup>(4)</sup> (Supplemental Appendix S4A, Black 2006, Table 3 provides details regarding number of subjects and fractures in each arm, by fracture type). Further analyses for risk stratification in the FLEX trial are discussed in the section below entitled “Risk stratification from the alendronate and zoledronic acid extension studies,” and illustrated in the rest of Supplemental Appendix S4A.

In the HORIZON study extension, 1233 postmenopausal women who had already received three annual iv infusions of ZOL 5 mg were randomized to either continue yearly ZOL (Z6) for an additional 3 years or switch to placebo (Z3P3) in a blinded manner. All women received 1000 to 1500 mg of oral calcium and 400 to 1200 IU of vitamin D daily. The mean age was 75.5 ( $\pm 5$ )



**Fig. 1.** Risks associated with bisphosphonate use and other health outcomes. The likelihood of suffering fractures and other adverse events in adults is shown. For fractures, the risk of fractures on BP therapy and for stroke on aspirin therapy is illustrated. Fracture incidence rates are age-standardized, whereas for others they represent crude rates in the US. For atypical femoral fracture, the risks represent those reported while on BP therapy for 5 and 10 years. For osteonecrosis of the jaw, a single risk estimate is reported because of the paucity of evidence for a duration effect.

years, more than 95% were from primarily Western populations, and 5% were Asians. The subjects had a mean total femoral neck *T*-score of  $-2.6 (\pm 0.6)$ ; women over age 93 years or on other bone active drugs were excluded. Approximately 60% of the women had at least one prevalent vertebral fracture at entry into the extension.<sup>(7)</sup> The primary endpoint was percent change in femoral neck BMD between the two arms; secondary endpoints included BMD at other sites, fractures, bone turnover markers, and safety. Clinical fractures were identified similarly to the core study, self-reported with central adjudication. The incidence of morphometric fractures was assessed by comparison of radiographs at 3 years and 6 years.<sup>(7)</sup>

Subjects randomized to the Z3P3 arm had significantly greater femoral neck bone loss ( $-0.80$  versus  $0.24\%$ ;  $p = 0.0009$ ), and those in the Z6 arm had fewer morphometric spine fractures (RR = 0.51, 95% CI 0.26–0.95;  $p = 0.035$ )<sup>(7)</sup> (Supplemental Appendix S4B, Black JBMR 2012, Fig. 4). However, nonspine fracture risk did not differ among those who did and did not continue ZOL (RR = 0.99, 95% CI 0.7–1.5), and the same applied to hip fractures. This may be explained by low statistical power as shown in Supplemental Appendix S4B, Black JBMR 2012,<sup>(7)</sup> where Fig. 4 provides details regarding number of subjects and fractures in each arm, by fracture type. Further analyses for risk stratification in this trial extension are discussed in the section below entitled “Risk stratification from the alendronate and zoledronic acid extension studies,” and illustrated in the rest of Supplemental Appendix S4B.

## Differences Among Bisphosphonates

### Persistence of beneficial effects of BPs

Elevated bone turnover markers (BTMs) have been associated with low BMD and increased fracture risk in untreated

postmenopausal women.<sup>(35)</sup> In pivotal studies of BPs, a significant decrease in BTMs has been demonstrated.<sup>(25–28,31,33,36)</sup> Persistence of low BTMs may be a potential indication of continued beneficial effects after discontinuation of long-term BP use.<sup>(37)</sup> Withdrawal of BP treatment is associated with decreases in BMD and increases in BTMs, changes that differ among BPs. Based on these criteria, residual effects on BMD from ALN persist for 2 to 3 years and possibly 1 to 2 years for IBN and RIS.<sup>(4,37–39)</sup> In the case of 3 years of ZOL therapy, they extend for at least another 3 years.<sup>(7)</sup> These findings are consistent with the relative binding affinities of BPs for hydroxyapatite and human bone tissue.<sup>(19,40–43)</sup>

### Cost and convenience

Oral BPs are most frequently prescribed in part because of their low cost and convenience, and the costs of ALN, RIS, and IBN were found to be similar in a 2011 study.<sup>(44)</sup> Generic ALN, RIS, and IBN are now available in many countries worldwide. The availability of generic BPs may alter total health care costs. ZOL may also be a cost-effective first-line option compared with other branded BPs and, in some cases, even in comparison with generic ALN; however, these comparisons are limited by a paucity of compliance and persistence data, as well as by incomplete country-specific data.<sup>(45)</sup> Generic ZOL became available in the US in 2013 and in the UK in 2014, which may also change previous cost-effective analyses. Cost and availability of generic BPs vary among countries.

### Adherence

Adherence to osteoporosis therapies is essential to treatment efficacy, even with BPs, despite their long bone retention. Better

adherence to BP therapy is associated with larger increases in BMD,<sup>(46)</sup> and—when exceeding 75%—with lower rates of fracture.<sup>(18)</sup> A meta-analysis of 171,063 subjects followed for 1 to 2.5 years revealed a 46% increased fracture risk in noncompliant subjects versus compliant ones.<sup>(47)</sup> However, adherence is a major problem with currently available oral anti-osteoporosis therapies, with less than 50% of those starting oral BPs continuing them for more than 1 year. Major determinants of adherence to oral BPs are comorbidities and health plan costs. Reasons for discontinuation include side effects, concern about side effects, poor understanding of benefits, inconvenience, and use of multiple medications.<sup>(48–54)</sup> Persistence with intravenous BPs is not far superior to oral drugs, including the once yearly regimen. In a random sample of 5% of new users of IV ZOL in the Medicare database ( $N = 846$ ), 30% did not receive a second infusion.<sup>(55)</sup> Older age and receiving the infusion in a separate outpatient infusion center as opposed to a physician office predicted low adherence.<sup>(55)</sup> To date, evidence to establish superiority of intravenous versus oral BP is scarce and limited to short follow-up.<sup>(56)</sup> Patients with poorer adherence are expected to experience fewer serious adverse events such as ONJ and AFF. Adherence is an equally important consideration in patients being switched from one osteoporosis therapy to another (see below).

## Risk Stratification From the Alendronate and Zoledronic Acid Extension Studies

In an attempt to identify subgroups of subjects who may benefit most from longer-term therapy, investigators from both extension trials performed additional post hoc analyses.

### Potential risk stratification by BMD and prevalent or incident fractures

In the FLEX study, there was no significant effect of low BMD (stratified into three categories), nor of prevalent fractures, on the reduction in nonvertebral and clinical vertebral fracture with continued ALN versus placebo ( $N = 10$  subgroup comparisons), the only exception being a reduction in clinical vertebral fractures in subjects with femoral neck  $T$ -score between  $-2$  and  $-2.5$  (RR = 0.22, 95% CI 0.05–0.74)<sup>(4)</sup> (Supplemental Appendix S4A, Black 2006, Table 4). However, in these analyses, the subgroups categorized by  $T$ -scores may have had prevalent vertebral fractures. Similarly, those with prevalent fractures may have had a wide range of BMD. Therefore, additional analyses were conducted to evaluate the effect of continued ALN for 10 years in FLEX women with or without previous vertebral fractures at entry into FLEX, stratified by BMD categories, on morphometric and nonspine fractures.<sup>(5)</sup> Of a total of 12 subgroup analyses, the only significant finding was a reduction in nonspine fractures in women who did not have vertebral fractures and with femoral neck  $T$ -score  $\leq -2.5$  at FLEX baseline, who continued ALN for an additional 5 years compared with women who were switched to placebo (RR = 0.50; 95% CI 0.26–0.96)<sup>(5)</sup> (see Supplemental Appendix S4A, Schwartz 2010, Table 2). Finally, in the most recent post hoc analyses from FLEX, both femoral neck and total hip  $T$ -scores, entered as tertiles at study extension, predicted the occurrence of any clinical fracture after ALN discontinuation in subjects randomized to placebo in extension, proportions increasing from less than 10% to 30% from highest to lowest tertile<sup>(57)</sup> (Supplemental Appendix S4A, Bauer 2014, Fig. 2). Similarly, age (as a continuous


variable) and hip BMD  $T$ -score (lowest versus other two tertiles), at time of ALN discontinuation, predicted clinical vertebral fractures during the subsequent 5 years<sup>(57)</sup> (Supplemental Appendix S4A, Bauer JAMA Int Med 2014, Table 3).

In the HORIZON extension, additional analyses were performed to identify predictors of fractures in subjects who were randomized to placebo at 3 years.<sup>(58)</sup> By univariate analysis, the incidence of morphometric vertebral fractures in the Z3P3 group was predicted by femoral neck and total hip  $T$ -score  $\leq -2.5$ <sup>(58)</sup> (Supplemental Appendix S4B, Cosman 2014, Fig. 1). The odds ratio (OR) for femoral neck  $T$ -score  $\leq -2.5$  was 3.3 (CI 1.4–8), for total hip  $T$ -score  $\leq -2.5$ , 4.0 (CI 1.8–8.9), and for incident morphometric fractures during the core study, 4.8 (CI 1.4–16.8)<sup>(58)</sup> (Supplemental Appendix S4B, Cosman 2014, Table 2). Similarly, the incidence of nonvertebral fractures was predicted by total hip  $T$ -score as a continuous but not categorical variable, prevalent vertebral fracture (hazard ratio [HR] = 3.0 [CI 1.4–6.3]), and incident nonvertebral fractures during the core study (HR = 2.5 [CI 1.2–5.3])<sup>(58)</sup> (Supplemental Appendix S4B, Cosman 2014, Table 3). Finally, neither age  $\geq 75$  years, nor weight  $\leq 60$  kg, when entered as single categorical variables, was predictive of new morphometric or nonvertebral fractures in the Z3P3 subjects. The absolute risk of morphometric vertebral fracture in subgroups defined by single or combined risk factors is shown in Supplemental Appendix S4B, Cosman 2014 Table 4.<sup>(58)</sup> The absolute risk of such fracture remained low (3.1%) in women who only had one risk factor, eg, only a femoral neck BMD  $T$ -score  $\leq -2.5$ .

In a second extension of the HORIZON trial, 190 women who had received six prior annual infusions of ZOL were rerandomized to three more infusions or three placebo infusions. There was no significant difference in the rate of bone loss between the women who received 9 years of ZOL compared with those who received six annual infusions followed by 3 years of placebo. There were few fractures during the second extension, and there was no difference in fracture rates between the two groups.<sup>(59)</sup>

In summary, the extension studies reveal that 10 years of therapy with ALN and 6 years with ZOL prevented bone loss at multiple skeletal sites and a reduction in vertebral fractures compared with stopping ALN after 5 years or ZOL after 3 years. Subjects who seemed to benefit most from long-term ALN or ZOL therapy are those categorized as high risk, best captured by a persistent low  $T$ -score at hip ( $\leq -2.5$  in HORIZON for total hip or femoral neck  $T$ -score and above  $-2.5$  but  $\leq -2$  for femoral neck in FLEX), or incident fracture during the core study in HORIZON. However, the benefit in terms of fracture reduction was not entirely consistent across the two studies. Continued ALN resulted in a lower risk of clinical vertebral fractures, whereas ZOL resulted in a lower risk of morphometric vertebral fractures. The reason for this discrepancy is unclear, but possible factors include different baseline characteristics at entry into the extensions and in fracture incidence after treatment discontinuation. These data must be viewed with caution because of potential selection bias, small sample sizes, low numbers of fractures, the post hoc exploratory nature of many analyses, and lack of correction for multiple comparisons.

Based on these findings, continued BP therapy beyond 3 years with ZOL and beyond 5 years with ALN may be an option in high-risk individuals, based on evidence for reductions in the risk of vertebral fractures only. In lower-risk patients and in light of lack of evidence for fracture reduction with long-term therapy, discontinuation of treatment beyond 3 to 5 years, with



**Fig. 2.** Approach to the management of postmenopausal women on long-term bisphosphonate therapy. (1) From the registration trials, the benefits of 5 years of therapy clearly outweigh the risks. For treatment up to 10 years with oral bisphosphonates (FLEX extension) and 6 years with intravenous bisphosphonates (HORIZON extension), estimates of benefits and risks are based on much weaker data. For patients who fracture on therapy, assess adherence and rule out secondary causes of osteoporosis. Management of high risk patients is discussed in the text. (2) The benefits of switching to an alternative anti-fracture therapy after prolonged bisphosphonate treatment have not been adequately studied. (3) Based on FLEX and Horizon extension study (Caucasian women), may not apply to other populations. (4) High fracture risk: defined by older age (70–75 years), other strong risk factors for fracture, or FRAX fracture risk score that is above country specific thresholds. The use of FRAX in patients on therapy was only assessed in the Manitoba observational cohort.<sup>(66)</sup> (5) Reassessment includes clinical evaluation, risk assessment including risk factors, and may include bone density measurement by DXA. The monitoring interval with DXA should be based upon changes that are detectable and clinically significant. Reassessment may be necessary at less than 2 years in patients with a new fracture, or in light of anticipated accelerated bone loss (e.g. institution of aromatase inhibitor or glucocorticoid therapy).

monitoring, may be considered with periodic reassessment of fracture risk.

#### Potential risk stratification by bone turnover markers

BTMs are affected by BP therapy and are potentially useful in determining fracture risk before and after therapy has commenced. The 2010 AACE Clinical Practice Guideline stated that BTMs may be used at baseline to identify patients with high bone turnover and can be used to follow the response to therapy, although this was supported only by Grade C level evidence.<sup>(22)</sup> Recently, the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommended serum procollagen type I N-terminal peptide (P1NP) to assess bone formation and serum C-terminal cross-linking telopeptide (CTX) to assess bone resorption.<sup>(60)</sup>

Although the IOF and IFCC recommended the use of specific BTMs, it remains unclear how such BTMs should be used in clinical practice. Clinical studies have suggested their use as a primary fracture prediction tool, but many clinicians use BTMs to monitor osteoporosis treatment. A post hoc analyses of the Fracture Intervention Trial reported that greater reduction of serum P1NP, bone-specific alkaline phosphatase (BSAP), and

CTX in ALN-treated subjects was positively associated with fewer vertebral fractures.<sup>(61)</sup> Similar data were reported with RIS when reduction of markers was assessed by changes exceeding the least significant change,<sup>(62)</sup> but not for ZOL when a discrete cut-off above or below the lower limit of premenopausal age was used.<sup>(63)</sup>

The bone turnover markers CTX, PINP, and BSAP, measured in 76 women who took part in the FLEX trial, did not predict bone loss at the lumbar spine, total hip, or femoral neck over a 5-year treatment-free period in women who discontinued ALN after a mean of 5 years.<sup>(34)</sup> Similarly, a change in BSAP or urinary NTX/Cr was not associated with fracture risk when measured 1 year after drug discontinuation in 437 study subjects.<sup>(57)</sup> Fasting serum PINP, measured in 1140 women at entry in the HORIZON extension, was not a predictor of morphometric or nonvertebral fractures in the Z3P3 group.<sup>(58)</sup> BTM changes reported in large groups of patients may not be observed in individuals because of the variability in BTM tests.

At this time, based on the limited evidence from FLEX and HORIZON extension studies, there is no evidence to support the measurement of BTMs to assess fracture risk after long-term BP use or in offset periods. However, some experts use BTMs to determine whether a discontinued BP is still exerting its effects and resume therapy when they exceed the lower half of the

premenopausal range. This approach is based on the evidence that maintenance of BTMs in the lower range is associated with lower risk of fracture and the rationale that such observations can be extended to patients who discontinue BPs after long-term therapy.<sup>(60)</sup>

### Potential risk stratification by fracture risk calculators, age, and weight

For untreated patients, fracture risk calculators have been developed to identify individuals who may not have osteoporosis by DXA but are at high fracture risk nonetheless. The algorithm-based calculators that have been validated in at least one independent cohort from the original derivation cohort are the World Health Organization FRAX tool, the Garvan Risk Calculator, and the QResearch Database Qfracture.<sup>(64)</sup> To date, FRAX has been incorporated in some national osteoporosis guidelines and care pathways, but the evidence for its usefulness in treated patients is limited. In one study using the Manitoba database,<sup>(65)</sup> Leslie and colleagues demonstrated that FRAX scores in patients on osteoporosis therapies predicted 10-year risk of major osteoporotic fractures and hip fractures, except for the subgroup of adherent patients at highest risk, where hip fracture risk was overestimated by 30%.<sup>(66)</sup> The same authors also demonstrated in a subsequent publication that FRAX scores slowly increased over time. This increase was attenuated but not prevented by treatment, and a change in FRAX score on therapy did not independently predict incident fracture.<sup>(65)</sup> This is not surprising because FRAX includes both age and femoral neck BMD, which will likely affect the FRAX calculation in opposite directions over time in the treated patient.

Age and body mass index (BMI) are two of the most powerful predictors of fractures in general and play a key role in FRAX. These factors were independently evaluated in the FLEX study, and although older age and low BMI were associated with bone loss at the spine and hip after discontinuation of ALN therapy in univariate analyses, no model based on these risk factors was able to predict bone loss rate in the adjusted analyses.<sup>(34)</sup> However, age and hip BMD at discontinuation predicted clinical fracture in the 5 years after discontinuation.<sup>(57)</sup> In contrast, in the HORIZON extension study,<sup>(58)</sup> neither age ( $\geq 75$  years) nor weight ( $\leq 60$  kg) at entry into the extension or weight loss during the core trial was a predictor for the occurrence of morphometric vertebral or nonvertebral fractures in the group that discontinued ZOL after 3 years.

### Stopping Bisphosphonates and Restarting Therapy

As described above, after 3 years of intravenous ZOL and 5 years of oral ALN treatment, high-risk postmenopausal white women, such as those with recent incident fracture in the HORIZON extension, or with low hip T-scores in both studies appeared to benefit the most from continued BP treatment. The evidence for this benefit is limited to reducing the risk of vertebral fractures, and data for other BPs are lacking. Furthermore, tools to identify subjects who will fracture when therapy is discontinued are limited. History and physical examination can provide information about additional clinical risk factors that may further increase fracture risk, such as older age, low BMI, weight loss, fall history, or the intake of drugs that have adverse effects on bone. Attention to causes of secondary osteoporosis, calcium intake,

and vitamin D levels may also affect response to therapy. Two observational studies suggest that the serum 25-hydroxyvitamin D level should be 30 ng/mL or more to ensure an adequate response to BPs.<sup>(67–69)</sup> However, vitamin D status did not affect the bone density response to ALN in FIT.<sup>(67)</sup>

After treatment for 5 years with ALN and 3 years with ZOL, in postmenopausal women who have a low fracture risk with a hip T-score higher than  $-2.5$ , discontinuation of BP therapy may be considered with reassessment at 2 to 3 years after discontinuation to determine risk. Patients treated with RIS may need earlier reassessment because of the shorter biologic half-life of this BP.<sup>(70)</sup> Repeat DXA or BTM measurements may be considered during this “holiday,” but there are no data to guide the clinician regarding reinstatement of therapy because neither 1-year change in BMD nor 1 year change in BTMs predicted fractures post-BP discontinuation.<sup>(57)</sup> It would be reasonable to consider withholding therapy as long as BMD is stable and to restart BP therapy (or an alternate osteoporosis medication) if the BMD T-score is  $\leq -2.5$ , or if other new/additional risk factors for fractures emerge. However, this approach is based on expert opinion. Furthermore, the use of a T-score cut-off of  $-2.5$  for risk stratification and decision-making regarding therapy discontinuation is based on studies conducted almost exclusively in community-dwelling, postmenopausal white women. Although the relative risk for fracture/standard deviation decrease in BMD is best described by an inverse exponential relation that is similar across populations worldwide, the absolute fracture risk incurred by the same BMD T-score may be higher in more frail postmenopausal women and lower in some non-white populations than in white women.

### Safety of Bisphosphonates and Effect of Discontinuation on Adverse Events

Although some side effects of BPs, such as gastroesophageal irritation and nephrotoxicity (see below), were recognized early as potential adverse effects, subsequent reports indicate that BP use may be associated with clinically serious but rare safety concerns, including osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs). These are not unique to BPs and have been reported with denosumab, another potent antiresorptive agent, and also occur in people who have not been treated with any of these agents.

#### Osteonecrosis of the jaw (ONJ)

ONJ was first associated with bisphosphonate therapy in a report in 2003, in patients with metastatic cancer receiving high-dose intravenous BP therapy. ONJ is characterized by 1) exposed necrotic bone in the maxillofacial region that has been present for at least 8 weeks of appropriate therapy; 2) exposure to potent antiresorptive agents (BPs or denosumab) or anti-angiogenic agents; and 3) no history of radiation therapy to the jaw.<sup>(71)</sup> In one study,<sup>(72)</sup> the incidence in patients not on BPs was 1/3000 patient-years. The pathogenesis of ONJ remains unclear,<sup>(17,73)</sup> but several potential mechanisms, which are not necessarily mutually exclusive, have been proposed. These include over-suppression of bone remodeling, infection, inhibition of angiogenesis, soft tissue toxicity, and immune dysfunction. In patients receiving BP therapy for osteoporosis, current estimates of the incidence of ONJ range from approximately 1/10,000 to 1/100,000 patient treatment years.<sup>(8)</sup> Potential factors increasing the risk for BP-treated patients to develop ONJ include poor oral

hygiene, smoking, diabetes mellitus, concomitant glucocorticoid and/or chemotherapy use, and invasive dental procedures, such as dental extractions or implants. The incidence may be higher in Asian populations, pointing to a genetic predisposition, as recently reported in Taiwanese subjects.<sup>(74)</sup> For the vast majority of patients with osteoporosis treated with BPs who develop ONJ, the clinical course is mild and self-limited, and the condition can be treated conservatively.<sup>(8,17,75)</sup> Preventive practices that may reduce the incidence of ONJ include prophylactic dental care and avoidance of invasive dental procedures. Detailed recommendations for management have been provided by the ASBMR,<sup>(8)</sup> the American Dental Association,<sup>(75)</sup> the American Association of Oral and Maxillofacial Surgeons,<sup>(76)</sup> and the recently updated report of an International Task Force.<sup>(17)</sup> Although there appears to be a trend for an increased risk of ONJ with duration of BP use, the quality of the evidence for such association is poor.<sup>(17)</sup> A Drug Safety Update was just released by the Medicines and Healthcare Products Regulatory Agency regarding the risk of ONJ with intravenous BPs and denosumab.<sup>(77)</sup> Risk factors for ONJ may be included in the periodic reassessment of benefits and risks of BP therapy.<sup>(78)</sup>

### Atypical femur fractures (AFFs)

The relationship between AFFs and BPs was first reported in 2005 in patients receiving oral BPs for osteoporosis.<sup>(10)</sup> In a large retrospective analyses of >1.8 million adults, including approximately 10% who had been treated with BPs, 142 AFFs were identified, including 128 in subjects with prior BP exposure.<sup>(11)</sup> These fractures usually occur with little or no antecedent trauma, are often preceded by thigh or groin pain, and may occur bilaterally.<sup>(10,79)</sup> Updated diagnostic criteria were published in 2014.<sup>(9)</sup> The diagnosis of AFF is based on subtrochanteric or femoral shaft location and the presence of at least 4 of 5 major criteria: minimal trauma, fracture originating at the lateral cortex and being substantially transverse, complete fractures extending through both cortices, localized periosteal or endosteal cortical thickening, and minimal comminution at most. Minor criteria are not required for the diagnosis but include increased cortical thickness of the femoral diaphysis, bilaterality, a prodrome of thigh or groin pain, and delayed fracture healing. In terms of incidence rates, some but not all studies suggest a duration response relationship, with a rise in age-adjusted incidence rates from 1.8/100,000 per year with a 2-year exposure to 113/100,000 per year with exposure from 8 to 9.9 years.<sup>(11)</sup> Such results strongly suggest that although a rare potential complication of BP use, AFF risk increases with prolonged duration of BP treatment and that this should be taken into consideration when continuing BPs beyond 5 years. However, it is important to note that for most patients treated for osteoporosis, the BP-associated benefit of reduced fracture risk beyond 5 years, albeit with evidence for vertebral fracture only, is greater than the risk of developing either ONJ or an AFF (Fig. 1). Based on the information provided in Fig. 1, it is possible to estimate benefits and risks for BP therapy for the first 5 years of therapy. For up to 5 years of BP therapy, approximately 175 hip fractures, 1470 vertebral fractures, and 945 wrist fractures would be averted (2590 total/100,000) for 16 AFFs/100,000 associated with treatment, for a total of 162 fractures of the spine, hip, or forearm prevented/AFF potentially caused. For years 5 to 10 of BP therapy, there are insufficient data to estimate the number of fractures averted by BPs because the only studies available were underpowered for fracture endpoints.

### Other risk factors for AFF

Limited data exist regarding AFF risk factors other than BPs. Recently it has been postulated that a smaller femoral neck-shaft angle predisposes to AFF.<sup>(80)</sup> In addition, bowing of the femur may be associated with increased AFF risk.<sup>(81)</sup> Whether these or other patient characteristics can help determine the risk/benefit ratio for BP therapy duration is not established. Documented AFFs have also been described among individuals treated with denosumab, and the impact of duration of denosumab use on the risk of AFF remains unknown to date, in view of the rather limited data with long-term denosumab use.<sup>(82,83)</sup> An increased risk of AFF has been postulated in glucocorticoid and proton pump inhibitor users, individuals with diabetes and rheumatoid arthritis, and individuals of Asian ancestry. In one study, many of the patients with AFF were younger, active women with osteopenia; it is possible that many were not at high risk for typical fracture.<sup>(84)</sup>

Reports of AFF with denosumab therapy should be kept in mind when considering switching from BP to denosumab therapy, and a careful scrutiny of the relevant risk factors for AFF should be performed.<sup>(85)</sup> Importantly, documented AFFs have also occurred in individuals without any history of antiresorptive therapy.

### Other adverse events associated with BP therapy

Other potential adverse events have been reported to be increased in patients receiving BP therapy but are not included in this review because they are neither clearly related to BP use nor to therapy duration. These include esophageal cancer, atrial fibrillation, acute kidney injury, acute phase reaction (mostly noted after the first administration of an intravenous BP), musculoskeletal pain, and gastrointestinal intolerance. The strength of the association between BP use and atrial fibrillation and with esophageal carcinoma is weak at best,<sup>(86)</sup> and the FDA has not ordered warnings for either atrial fibrillation or esophageal carcinoma in package inserts for oral BPs. It is usually possible to avoid renal injury by only using BPs in patients with a creatinine clearance > 30-35 ml/min.<sup>(87)</sup> Intravenous BPs can be used in those patients with gastrointestinal intolerance or contraindications to oral BPs.

### Side-Effect Risks after Stopping Bisphosphonate Treatment

Effect of bisphosphonate discontinuation (holiday) on AFF risk

There are few data estimating the risk of AFF after stopping BPs. Of the 3 large cohort studies, only the Swedish study by Schilcher included information about the risk of AFF after stopping treatment.<sup>(12)</sup> The risk fell by 70%/year since last BP use (odds ratio [OR] = 0.28, 95% CI 0.21–0.38), and the most dramatic reduction in risk occurred after the first year of discontinuation. Specifically, compared with those without BP exposure, the relative risk of confirmed AFF was 43 in the first year after discontinuation and 3.5 after the first year, but these analyses were based upon a total of 46 AFF events and only 4 AFFs occurred >1 year after discontinuation of BP. The derived estimates may have been overestimated in view of short-term follow-up in this cohort.<sup>(13)</sup>



## Effect of bisphosphonate discontinuation on ONJ risk

Because of the long-terminal half-life of BPs, the American Dental Association<sup>(75)</sup> and the American Association of Oral and Maxillofacial Surgeons<sup>(76)</sup> do not recommend routine discontinuation of BP treatment for osteoporosis in most patients about to undergo invasive dental procedures. There are no studies of the incidence of ONJ in patients at different times after discontinuation of BP treatment for osteoporosis.

## Potential use of BTMs to determine safety risks

The value of BTMs to predict which patients on long-term BPs are at risk for AFFs is unclear. Markedly suppressed bone turnover leading to an inability to repair skeletal microfractures, followed by propagation of these small fractures, has been proposed as the mechanism underlying AFFs.<sup>(9,10,88,89)</sup> The second report of a task force convened by the ASBMR to examine atypical subtrochanteric and diaphyseal femur fractures identified published reports in which AFFs had been confirmed by radiologic review.<sup>(9)</sup> Two small case series examined the association of BTMs with AFFs.<sup>(90,91)</sup> Odvina and colleagues reported 9 patients with “spontaneous nonspinal fractures” on long-term (range 3 to 8 years) BPs. By dynamic histomorphometry, all had suppressed bone formation and 8 of 9 had low resorption. The correlation of bone histomorphometric parameters with BTMs was poor. Urine NTX was low to mid normal in 7 subjects, and although serum BSAP levels ranged widely, serum osteocalcin was low or at lower limit of the reference range at the time of bone biopsy.<sup>(90)</sup> Visekruna and colleagues reported on 3 subjects who experienced spontaneous “minimal-trauma chalk-stick type metadiaphyseal femoral fractures” while on long-term BPs. Serum NTX was low in only one of the subjects.<sup>(91)</sup> Similarly, both the American Dental Association recommendations<sup>(75)</sup> and the American Association of Oral and Maxillofacial Surgeons<sup>(76)</sup> conclude that measurement of BTMs does not help in the assessment of risk of ONJ in patients on BPs for osteoporosis.

## Bisphosphonate safety concerns in perspective with other medical and nonmedical safety issues

To provide a perspective of the safety concerns associated with BP therapy, Fig. 1 illustrates the incidence of ONJ and AFF and that of typical osteoporotic fractures in various countries, as well as some other important outcomes and serious events. The age-standardized incidence rate of hip fractures (after age 50 years) is elevated across all continents.<sup>(92)</sup> Among women in the US, the age-adjusted annualized rates for fracture greatly exceeds that of other diseases in the elderly, such as heart attack (2-fold), breast cancer (4.7-fold), and stroke (8.5-fold).<sup>(93)</sup> For other health outcomes, CDC outcome data are expressed as crude rates for pedestrian injuries and murder.<sup>(94,95)</sup> The risk of fractures is substantially decreased by BPs and remains much higher than that of developing risk of ONJ or AFF (Fig. 1).<sup>(11,72)</sup> As a comparison, the risk of stroke is decreased by aspirin therapy, but the risk of intracerebral bleed is increased to a comparable degree.<sup>(96)</sup>

## Management of adverse events related to bisphosphonates

When ONJ or an AFF occurs in a patient on chronic BPs for osteoporosis, discontinuation of the BP is recommended.

The American Association of Oral and Maxillofacial Surgeons recommends treatments based on the stage of ONJ.<sup>(76)</sup> Such treatment may include antibacterial mouth rinse, oral antibiotics, and surgical debridement. Good dental hygiene and patient education are emphasized for all patients on anti-resorptive drugs.<sup>(75)</sup> Specific recommendations for prevention, operative, and medical management of ONJ have been reviewed recently.<sup>(75,76)</sup>

In the past few years, numerous case reports and small prospective studies have reported healing of AFF or ONJ, typically occurring within a few months of starting teriparatide therapy.<sup>(97–100)</sup>

In addition, a few reports have demonstrated a beneficial effect of strontium ranelate in AFF.<sup>(97–99)</sup> Based on available reports, a limited course of teriparatide may be considered to accelerate healing of BP-related AFFs or ONJ, consistent with the recommendations of the ASBMR Task Force on Atypical Femoral Fractures and the International Consensus report on ONJ.<sup>(9,17)</sup>

## Efficacy and Safety of Alternative Drugs

A summary of efficacy of alternative therapies is provided in Table 1 and an overview is provided in Supplemental Appendix 5. For detailed reviews on alternative osteoporosis therapies, the reader is directed to published reviews.<sup>(100,101)</sup> In women previously treated with oral BPs, switching to denosumab was associated with greater increases in BMD and reduction of turnover markers than continued intake of ALN,<sup>(102)</sup> RIS,<sup>(103)</sup> and IBN,<sup>(104)</sup> and comparison with ZOL is still ongoing.<sup>(105)</sup> However, no information on fracture occurrence after changing therapy is available.<sup>(102,106)</sup>

## Potential additional benefits of bisphosphonate treatment

Side effects of BPs may include beneficial effects, although most evidence is from observational studies. For example, previous studies have reported that some types of cancer may be found less commonly in BP users, such as breast cancer,<sup>(107)</sup> colon cancer,<sup>(108)</sup> and gastric cancer.<sup>(109)</sup> A recent review of osteoporosis registration trials, however, did not show reduced incidence of breast cancer in patients treated with ALN or ZOL,<sup>(110)</sup> although there may be potential positive effects of BPs in women with established breast cancer.<sup>(111)</sup> In addition, there is some evidence that vascular disease may be decreased in patients treated with BPs, as manifested by lower risk of stroke<sup>(112)</sup> and myocardial infarction.<sup>(113)</sup> There are also some reports that mortality is reduced in patients treated with BPs, although not all studies are positive.<sup>(54,114–119)</sup> The mechanisms underlying such putative beneficial effects are unclear. Finally, there is some evidence that a decreased incidence of pneumonia and arrhythmia after hip fracture may play a role in the reduced mortality noted in patients treated with ZOL.<sup>(120)</sup>

## Long-Term Osteoporosis Management With BPs

### A suggested approach

After review of the efficacy and safety data for BP treatment of osteoporosis, the ASBMR Task Force created an approach to aid decisions about the management of patients with osteoporosis on long-term BP therapy, as shown in Fig. 2.

**Table.** Efficacy of Osteoporosis-Approved Medications in North America and Europe by Approval Indication and by Skeletal Site for Fracture Reduction (Updated December 2014, <http://www.aub.edu.lb/fm/cmop/downloads/e-summary.pdf>).

	Postmenopausal osteoporosis				Fracture risk reduction		
	Prevention	Treatment	Men	GIO <sup>a</sup>	Vertebral fracture	Hip fracture	Nonvertebral fracture
<b>Anti-remodeling agents</b>							
Alendronate	✓	✓	✓	✓	PMW	PMW	PMW
Ibandronate	✓	✓	-	-	PMW	-	PMW <sup>b</sup>
Risedronate	✓	✓	✓	✓	PMW	PMW	PMW
Zoledronic acid	✓	✓	✓	✓	PMW and M <sup>c</sup>	PMW and M <sup>c</sup>	PMW and M <sup>c</sup>
Bazedoxifene <sup>d</sup>	✓	✓	-	-	PMW	-	PMW <sup>e</sup>
Lasofloxifene <sup>d</sup>	✓	✓	-	-	PMW	-	PMW
Raloxifene	✓	✓	-	-	PMW	-	-
Denosumab	-	✓	✓	-	PMW <sup>f</sup> and M <sup>f</sup>	PMW	PMW <sup>f</sup>
Estrogen	✓	-	-	-	PMW	PMW	PMW
Conjugated estrogen/ bazedoxifene <sup>g</sup>	✓	-	-	-	-	-	-
Calcitonin <sup>h</sup>	-	✓	-	-	PMW	-	-
Tibolone <sup>d</sup>	✓	-	-	-	PMW	-	PMW
<b>Anabolic agents</b>							
Teriparatide	-	✓	✓	✓	PMW and M <sup>i</sup>	-	PMW
<b>Others</b>							
Strontium ranelate <sup>j,d</sup>	✓	✓	✓	-	PMW	PMW <sup>k</sup>	PMW

PMW = postmenopausal women; M = men. <sup>a</sup>GIO<sup>a</sup> fracture data: One alendronate and one risedronate trial each showed a significant reduction in vertebral fractures compared with placebo; one trial showed that teriparatide significantly reduced vertebral fractures compared with alendronate. One trial compared zoledronic acid with risedronate and showed no significant difference in vertebral fracture reduction. There are no studies comparing zoledronic acid or teriparatide with placebo.

<sup>b</sup>Post hoc analysis, in women with FN BMD T-score < -3. <sup>c</sup>Same study included men and women and there was no treatment by sex interaction; there was a lack of a statistically significant fracture reduction in men subpopulation, as the sex-based subset analysis was powered for a BMD endpoint and not for antifracture efficacy. Vertebral fracture reduction has been demonstrated in another trial conducted exclusively in men.

<sup>d</sup>Only approved in Europe.

<sup>e</sup>Post hoc analysis. Femoral Neck T-score ≤ -3 or ≥ 1 moderate or severe vertebral fracture or multiple mild vertebral fractures.

<sup>f</sup>The ABCSG trial in postmenopausal women on aromatase inhibitors demonstrated a reduction in both both vertebral fractures and any clinical fractures, trial in men with prostate cancer on androgen deprivation therapy.

<sup>g</sup>Approval indication: FDA approval for osteoporosis prevention and European Medicines Agency approval for estrogen-deficiency symptoms.

<sup>h</sup>Calcitonin withdrawn from EU market, available in US for restricted conditions. See main text and FDA link. In all study groups, there was a significant reduction in moderate to severe fractures in the combined group (teriparatide 20 mcg and 40 mcg). In the subgroup of men who had prevalent fracture at baseline, there was a significant reduction in all vertebral fractures in the combined group (teriparatide 20 mcg and 40 mcg) and a significant reduction in moderate to severe vertebral fractures in each group separately.

<sup>j</sup>Approved by EMEA with restrictions: "Strontium ranelate is now restricted to the treatment of severe osteoporosis in postmenopausal women and adult men at high risk of fracture who cannot use other osteoporosis treatments because of, for example, contraindications or intolerance. The risk of developing cardiovascular disease or cerebrovascular disease should be assessed before starting treatment. Treatment should not be started in people who have or have had ischemic heart disease or peripheral arterial disease or cerebrovascular disease or uncontrolled hypertension. Cardiovascular risk should be monitored every 6-12 months. Treatment should be stopped if the individual develops ischemic heart disease, peripheral arterial disease, or cerebrovascular disease, or if hypertension is uncontrolled."

<sup>k</sup>Subgroup of high-risk postmenopausal women, aged ≥74 years and femoral neck bone mineral density T-score ≤ -3, corresponding to -2.4 according to NHANES reference.

Because registration trials that demonstrated the antifracture efficacy of BPs<sup>(25,26,28–31)</sup> and their corresponding extension studies with continuation or discontinuation of therapy thereafter<sup>(4,7,58)</sup> have been exclusively conducted in postmenopausal women, the approach pertains to the management of this specific patient population. Based on these trials and post hoc analyses of data from trials that exclusively used ALN and ZOL,<sup>(4,5,57,58)</sup> the Task Force determined that for postmenopausal women who have been on oral BP therapy for 5 years or intravenous ZOL for 3 years, but less than 10 years, a major consideration was whether the particular patient had experienced a hip, spine (including asymptomatic vertebral compression fractures found by serial height measurements and/or images before therapy discontinuation), or multiple other osteoporotic fractures before therapy, or experienced a major osteoporotic fracture (spine, hip, humerus, or forearm) while on therapy. Because such fractures, especially when recent (ie, experienced within 3 to 5 years), increase future fracture risk,<sup>(58,121–125)</sup> the Task Force suggests that providers discuss with patients about the option of continuing oral BP therapy for up to a total of 10 years. For IV BP use, the approach pertains to <6 years of ZOL. Patients who sustain a major osteoporotic fracture while on therapy should also undergo evaluation for causes of secondary osteoporosis, new risk factors, and assessment of adherence with medication. In addition, switching to alternative therapies may be considered, although there have not been adequate studies to evaluate the efficacy of such an approach. The optimal length of therapy for the patient who suffers a fracture while on treatment has not been established, and clinical judgment will be needed to determine each patient's specific fracture risk. In addition, the potential contributions of poor compliance or adherence to therapy, inadequate vitamin D status, high fall risk, or new risk factors should be taken into consideration.

In addition to recent fracture, other potential variables that may signal increased fracture risk and that could be used for the decision on whether to continue therapy include older age (for example, >70 to 75 years), medication use (eg, aromatase inhibitors, glucocorticoid therapy), or new diagnosis of a disorder associated with secondary osteoporosis. If the clinician determines that the patient remains at elevated fracture risk, based on femoral neck *T*-score, age, or other risk factors, the Task Force suggests that the provider discuss with the patient the option of continuing BP treatment for another 2 to 3 years with reassessment at that time. For those women who are not considered to be at high fracture risk by these limited tools, a drug holiday may be considered with reassessment at 2 to 3 years, perhaps with earlier assessment for those women treated with RIS. Alternative antifracture therapy could also be considered for those patients remaining at high risk for fracture. Alternative treatments would include the agents described in Supplemental Appendix S5: teriparatide and denosumab as first options, then raloxifene and, depending on the patient risk profile. Strontium ranelate could be considered in patients who cannot tolerate any of the above alternative therapies provided the patient is not at high risk for cardiovascular disease.

In view of the lack of definitive evidence to support a clinical pathway, although the Task Force–suggested approach can be regarded as an aid to making management decisions, it does not replace the need for clinical judgment in the care of individual patients. The approach was developed to reflect the data from two large clinical trials in which the majority of subjects were white American and European women. The limitations of the

suggested approach, risk stratification, and applicability to other groups are outlined in section below. Country-specific thresholds and those for non-white women for initial treatment vary, and so may thresholds for continuation or reinstatement of therapy.

## Limitations of the Proposed Approach

### Risk stratification by prevalent fractures

Risk stratification determined by history of fractures is based on evidence that this subgroup represents a high-risk category and one in which benefit may be derived from continued therapy for up to 10 years using ALN and 6 years with ZOL. This conclusion is derived from the HORIZON extension study only.<sup>(58)</sup> However, many patients with a history of major osteoporotic fractures are older, have experienced multiple osteoporotic fractures, and may have received BPs for more than 10 years. Although such patients remain at high risk for future fractures as they continue to age, with a consistent increase in fracture risk even when on treatment,<sup>(65)</sup> there is no evidence to guide clinicians on the best therapeutic option beyond 10 years. Such scenarios, therefore, could not be adequately addressed in the suggested approach (see illustrative cases in Supplemental Appendix S1).

### Risk stratification in patients without a history of fracture

In untreated patients, increasing age and decreasing bone density *T*-scores at the hip are well-established independent risk factors for fractures and predictive of response to therapy. The evidence for continued BP treatment efficacy based on a hip *T*-score  $\leq -2.5$  is limited to the FLEX and HORIZON extension trials that were conducted in older postmenopausal white women.<sup>(4,5,58)</sup> The evidence for age, BMI, and other risk factors from these studies is also quite limited. Age, entered as a continuous variable at entry into FLEX extension, was predictive of future clinical fractures<sup>(57)</sup> after discontinuation of ALN therapy.

To date, there are no trials that have tested the antifracture efficacy of switching therapies after 3 to 5 years of BP treatment, nor have any trials extended beyond 10 years, or assessed the utility of reinitiation of treatment after a drug holiday. The lack of good evidence for continued drug efficacy for prolonged periods is not unique to the field of osteoporosis and stems from the fact that most drug registration trials for chronic diseases last only 3 to 5 years, whereas approved therapies for such diseases are used for many more years. However, in the case of BPs, the increase in the risk of harms constitutes an additional challenge in the management of high-risk patients. The suggested approach, therefore, only constitutes a framework for decision making in patients on BP therapy for less than 10 years. This lack of solid evidence is unlikely to change and implies that a tailored approach, which includes assessment of each patient's individual risk profile, must be adopted. A thoughtful risk-benefit analysis, shared decision making with the patient, and careful follow-up are strongly recommended. Referral of the most challenging patients, such as those who are considered high risk and have been on BPs for more than 10 years or who fracture after several years of BP therapy, to an osteoporosis expert should also be considered. The illustrative cases described in Supplemental Appendix S1 provide some examples of challenges encountered in practice that could not all be

addressed by the suggested approach, and illustrate how clinical decisions may be reached. Lastly, the data available do not allow for a similar assessment for men with osteoporosis or for subjects with glucocorticoid-induced osteoporosis, topics discussed in the following section.

## Application of the Approach to Patients on Glucocorticoid Therapy or Men

### Long-term bisphosphonate therapy in individuals taking continuous oral glucocorticoids

Glucocorticoid-induced osteoporosis is a common cause of secondary osteoporosis and often requires long-term bone-protective therapy. Although bone loss and low BMD contribute to fracture in individuals treated with glucocorticoids, the increased fracture risk is partially independent of BMD, and fractures occur at a higher BMD than in other forms of osteoporosis.<sup>(126)</sup> As a consequence, most guidelines recommend that treatment be started at a higher *T*-score in women receiving long-term glucocorticoid therapy than in those not receiving glucocorticoids.<sup>(127,128)</sup>

The efficacy of BP therapy in women and men taking glucocorticoids has mostly been studied for only 1 to 2 years, with the exception of the comparator study of teriparatide versus ALN, for which 3-year data are available.<sup>(129–135)</sup> Furthermore, fracture has not been a primary endpoint of any of the treatment studies in glucocorticoid-induced osteoporosis. Post hoc or safety analyses have shown a reduction in morphometric vertebral fracture for ALN, etidronate, and RIS; in the comparator study of teriparatide versus ALN, teriparatide treatment was significantly more effective than ALN in reducing both morphometric and clinical vertebral fractures.<sup>(134)</sup> There is no evidence from any of the studies for a reduction in nonvertebral or hip fractures, but the number of subjects studied was small. See Table for approved BPs in glucocorticoid-induced osteoporosis.

Long-term safety data for BP therapy in women treated with oral glucocorticoids are also lacking. However, the increased prevalence of comorbidities and comedications in women treated with glucocorticoids might be expected to increase the risk of adverse events, particularly gastrointestinal side effects. In addition, there is evidence from some studies that glucocorticoid therapy may increase the risk of BP-associated AFF and ONJ, although this has not been a consistent finding.<sup>(86)</sup>

There is evidence that after cessation of glucocorticoid therapy, fracture risk decreases, although it is unclear whether it returns to baseline values.<sup>(136)</sup> If glucocorticoid therapy is withdrawn, cessation of BP therapy can, therefore, be considered, depending on BMD, fracture history, and other risk factors. If fracture risk remains high based on these factors, the Task Force suggests that treatment be continued. In women who continue to take glucocorticoids long term in a dose >5 mg/d of oral prednisolone or equivalent, continuation of bone-protective therapy is generally indicated.<sup>(128)</sup>

Current guidelines on the management of glucocorticoid-induced osteoporosis do not specifically address the issue of duration of therapy in patients treated with BPs.<sup>(127,128)</sup> However, in those women who require continued bone-protective therapy and who have received BPs for more than 5 years, switching to teriparatide may be considered. The ability of BMD measurements and/or fracture risk algorithms such as FRAX to predict fracture in individuals taking glucocorticoids

and treated with bone-protective therapy has not been tested. However, higher *T*-score thresholds than those used in postmenopausal osteoporosis, including the –2.5 hip *T*-score cut-off used in the proposed approach, may be appropriate in such patients, given the higher BMD at which fractures occur.

Most BP trials in patients on glucocorticoids were conducted in women and men. Thus, men older than 50 years who are treated with long-term glucocorticoids >5 mg/d are also at increased risk of fracture and may benefit from continuation of therapy.<sup>(127)</sup>

### Long-term bisphosphonate therapy in men

The efficacy of BP therapy in men has mostly been studied for 2 to 3 years, with extension studies proceeding for as long as 4 years.<sup>(137–142)</sup> ALN, RIS, and ZOL have been approved for treatment of osteoporosis in men but not IBN (Table). The optimal duration of therapy in men has not been determined. Unlike for postmenopausal women, fractures have not been the primary endpoint for any of the BP treatment studies in men except for a single ZOL trial.<sup>(143)</sup> There is no evidence from any of the studies for a reduction in nonvertebral or hip fractures in men (Table), although men were included in the ZOL post-hip fracture trial<sup>(118)</sup> in which a reduced fracture risk was demonstrated in the overall study population. Long-term safety data for BP therapies in men are also lacking. The prevalence of comorbidities and comedications in men might be expected to lead to similar risk of adverse events as in women. There is no evidence from studies that long-term BP therapy increases the risk of BP-associated AFF and ONJ more in men than in women. In one recent observational study,<sup>(144)</sup> AFF incidence was not related to BP treatment duration. There is no evidence that cessation of BP therapy in men leads to greater or more rapid increase in fracture risk than in women. It remains unclear how long it takes in men for fracture risk to return to baseline values before treatment, but presumably this is similar to postmenopausal women. If fracture risk remains high based on post-treatment BMD or other risk factors as suggested for postmenopausal women, continued treatment should be considered. In men who require continued bone-protective therapy and who have received BPs for more than 5 years, switching to teriparatide may be considered.

In light of these considerations, the approach developed by the ASBMR Task Force on Long-Term Bisphosphonates can be considered generally applicable to older men, although evidence in men is much scarcer than in postmenopausal women. Men on long-term BP therapy presumably have similar safety issues as postmenopausal women, with no greater risks identified in men. It would be reasonable to continue treatment in men on long-term therapy with a history of hip, spine, or multiple other osteoporotic fractures or major osteoporotic fracture while on therapy. For other men who have hip BMD *T*-scores above –2.5 and who are not considered high risk because of age or other risk factors such as androgen-deprivation therapy for prostate cancer, consideration of a drug holiday is reasonable for 2 to 3 years. Again, those men on RIS may need earlier reassessment. On the other hand, for men who have these types of fractures or have a hip BMD *T*-score at or below –2.5 or who are high risk, it is reasonable to continue treatment, with reassessment for possible drug holiday in 2 to 3 years. This conclusion is based on the evidence that changes in surrogates

for fracture (BMD) in response to BPs are similar in men and women. The IOF and ISCD recommend that a white female database be used for calculation of the *T*-score in men, as does the FRAX online calculator, whereas the NOF and Endocrine Society recommend the use of a white male database. The former approach would decrease the number of men who would be considered eligible for continued treatment after 3 to 5 years of BP. The impact of database selection in men on fracture prediction and actual fracture incidence was investigated by Ensrud and colleagues in treatment naive men from the MrOs cohort in the US.<sup>(145)</sup> The authors demonstrated that in the subgroup of men with osteoporosis exclusively defined by *T*-score using a female reference database, the proportion of subjects who actually experienced osteoporotic fractures (major or hip) were highest compared with those in the subgroup identified by the use of a male database or other subgroups.

## Conclusions

---

It is obvious that there is relatively little evidence on which the Task Force can base recommendations, and indeed we have presented management suggestions based on limited data and clinical experience. Risk stratification is an important consideration to guide therapy continuation in patients on long-term BPs, as it also should be in treatment naive individuals.

The risk of AFF is low, with an incidence of up to 50/100,000 during the first 5 years of BP, resulting in a clear positive benefit/risk ratio within this time frame. However, although the risk of AFF increases further with prolonged BP use, reaching up to 113/100,000 after 8 to 9 years, there is much less certainty about these estimates, thus rendering an assessment for a sustained positive benefit/risk ratio with more prolonged BP use quite challenging. Furthermore, sustained fracture efficacy with prolonged BP use has been shown for vertebral fracture only. The sample size of the extension studies was too small to enable detection of nonvertebral fracture risk reduction. Thus, the ultimate decision for a patient to continue long-term BP therapy beyond 5 years should take into consideration the limitations of the efficacy and safety studies. Patients' values and preferences should be integrated with the limited data available to enable individualized shared decision making.

The cases presented in Supplemental Appendix S1 demonstrate how individualization of management is achieved. For many of the challenges raised, studies do not exist to guide our practice, such as in the use of BPs beyond 10 years and long-term BP use in men or in patients on long-term glucocorticoid therapy. They also show that even if there were multiple randomized controlled studies on which the approach could be based, clinical judgment would still play an important role in taking care of patients with osteoporosis. As has been discussed in a series of papers on guidelines,<sup>(146)</sup> basing guidelines on randomized trials does not address the impact of coexisting conditions in many patients with a given disorder. This is particularly true for osteoporosis because most patients are older and very often have many comorbidities.

It is unlikely that there will ever be randomized controlled trials of osteoporosis patients of sufficient size and duration to provide clear evidence that a given strategy for long-term management leads to fewer osteoporotic fractures. Observational studies may provide some information, but they are

always affected by potential unmeasured confounders and by the fact that many patients are not adherent to osteoporosis therapy. With new medications in development, it may be possible to treat patients with a sequence of therapeutic agents in the hope that such a strategy will lead to fewer adverse events but improved fracture risk reduction. Nonetheless, the new drugs will likely be approved based on registration trials similar to the ones for existing approved drugs, and no trials are anticipated to address sequential therapies over extended periods of times. The clinician caring for the patient with the chronic disorder of osteoporosis will need to use the art in addition to the science of medicine. The approach created by the Task Force will be only one tool to help in clinical decision-making.

## Research needs and future directions

It is unlikely that additional evidence from the FLEX and HORIZON extension studies will result in major changes to the suggested approach in the near future. However, there is a pressing need to validate the use of FRAX or other fracture risk calculators in individuals on BP therapy. Similarly, investigations of additional tools or different approaches to use bone turnover or other markers to apply a personalized approach and identify high-risk individuals while on or off therapy, to detect those at higher risk for AFF or ONJ, and to monitor individuals off therapy are also needed. Studies of sequential therapy may identify new long-term strategies for fracture risk reduction. Finally, lessons learned from the prolonged BP therapy experience should be taken into account when developing protocols for extension studies for current and future therapies.

## Disclosures

---

The American Society for Bone and Mineral Research (ASBMR) is well served by the fact that many of those responsible for policy development and implementation have diverse interests and are involved in a variety of activities outside of the Society. Accordingly, the ASBMR requires all ASBMR Officers, Councilors, Committee Chairs, Editors-in-Chief, Associate Editors, and certain other appointed representatives to disclose any real or apparent conflicts of interest (including investments or positions in companies involved in the bone and mineral metabolism field), as well as any duality of interests (including affiliations, organizational interests, and/or positions held in entities relevant to the bone and mineral metabolism field and/or the American Society for Bone and Mineral Research).

The committees, task forces, and editorial boards of the ASBMR and its publications carry out the work of the Society on behalf of the membership. The distinct functions of the committees, task forces, and editorial boards are intended to address the broad mission of the ASBMR: to promote excellence in research and education, to integrate basic and clinical science in the field of bone and mineral metabolism, and to facilitate the translation of research into clinical practice and the betterment of human health. Chairs and members of committees, task forces, and editorial boards must assure that they act in these roles in a manner free from commercial bias and that they resolve any conflict or duality of interest or disclose them and then recuse themselves from related deliberations and voting. Below is a summary of disclosures from each task force member.

Robert Adler	McGuire VA Medical Center	Amgen	Consulting fees (other than Advisory Board or Board of Directors).	Individual	Under \$6,000	Current	Research consultant on 2 academic studies of osteoporosis treatment.
		Genentech	Research grants	Institution	\$6,000–\$20,000	Past	PI for investigator-initiated study of pituitary dysfunction in military traumatic brain injury. Study has ended.
		Merck	Research grants	Institution	\$6,000–\$20,000	Past	Completed study of odanacatib in men.
		Novartis	Research grants	Institution	\$6,000–\$20,000	Past	Completed extension study of zoledronic acid treatment of postmenopausal osteoporosis.
		Eli Lilly	Research grants	Institution	\$6,000–\$20,000	Past	Completed surveillance study of growth hormone replacement in adults.
		Amgen	Research grants	Institution	\$6,000–\$20,000	Past	Completed study of bisphosphonate adherence using large administrative databases. No past disclosures reported.
Douglas Bauer	University of California, San Francisco						No past disclosures reported.
Bart Clarke	Mayo Clinic College of Medicine						No past disclosures reported.
Gregory Clines	University of Michigan						No past disclosures reported.
Juliet Compston	University of Cambridge School of Clinical Medicine	GSK	Consulting fees (other than Advisory Board or Board of Directors).	Individual	Under \$6,000	Past	Advisory Board attendance.
		Servier	Honoraria or royalties	Individual	Under \$6,000	Past	Speaker at several national meetings.
		Warner Chilcott/University of Massachusetts	Research grants	Institution	>\$100,000	Past	Participation in GLOW study (Global Longitudinal Study of Osteoporosis in Women).
		Sanofi-Aventis/University of Massachusetts	Research grants	Institution	>\$100,000	Past	Participation in GLOW study.
		Nycomed	Research grants	Institution	>\$100,000	Past	Research grant for histomorphometric analysis of biopsies from PEAK study. Finished.
		Amgen	Honoraria or royalties	Individual	Under \$6,000	Past	Speaker at several national meetings.
		Warner Chilcott	Honoraria or royalties	Individual	Under \$6,000	Past	Speaker at national meeting.
		MSD	Consulting fees (other than Advisory Board or Board of Directors).	Individual	Under \$6,000	Past	Attendance at Advisory Board.
		Amgen	Honoraria or royalties	Individual	Under \$6,000	Past	Speaker at one national and one international meeting.
		GlaxoSmithKline	Research grants	Institution	>\$100,000	Past	Histomorphometric analysis of bone biopsies from HIV-positive individuals.
		Gilead	Honoraria or royalties	Individual	Under \$6,000	Past	Speaker at national and international meetings.
		Amgen	Consulting fees (other than Advisory Board or Board of Directors).	Institution	>\$100,000	Past	Member of Data Monitoring Committee for FREEDOM Study. Advisory Board attendance.

	Acuitas	Research grants	Institution	>\$100,000	Past	Study of MRI-based analysis of trabecular bone structure; no longer active.
	Medtronic	Consulting fees (other than Advisory Board or Board of Directors).	Individual	Under \$6,000	Past	Advice on submission to NICE HTA for vertebroplasty and kyphoplasty. Finished.
	Nycomed	Honoraria or royalties	Individual	Under \$6,000	Past	Speaker at several international meetings.
	Novartis	Consulting fees (other than Advisory Board or Board of Directors).	Institution	>\$100,000	Past	Member of Data Safety Monitoring Board for HORIZON study. Attendance at Advisory Board meeting.
	Sanofi-Aventis	Research grants	Institution	Under \$6,000	Past	Participation in GLOW study.
	MSD	Honoraria or royalties	Institution	Under \$6,000	Past	Speaker at national meeting
	Acuitas	Research grants	Institution	>\$100,000	Past	Study of MRI-based analysis of trabecular bone structure; no longer active.
Matthew Drake	Sanofi-Aventis	Research grants	Institution	Under \$6,000	Past	Participation in GLOW study. No past disclosures reported.
Beatrice Edwards	Mayo Clinic College of Medicine MD Anderson Cancer Center					
Ghada El-Hajj Fuleihan	Leis Laboratoires Services	Other	Institution	\$6,000–\$20,000	Current	Educational grant to hold a densitometry ISCD Academy Course.
Murray Favus	CVS/Caremark	Consulting fees (other than Advisory Board or Board of Directors).	Individual	Under \$6,000	Current	I provide educational information to professional advisory board and pharmaceutical staff on current information on osteoporosis including bone metabolism, pathophysiology, medication effects, and FDA-approved medications.
Susan Greenspan	Merck	Advisory Board	Individual	Under \$6,000	Current	Scientific advisory board for osteoporosis studies.
Ross McKinney	Amgen Lilly American Journal of Bioethics	Research grants Research grants Other	Institution Institution Individual	\$20,000–\$50,000 \$20,000–\$50,000 \$0	Current Current Current	PI for a research grant on osteoporosis therapy. PI for a research grant on therapy for osteoporosis. Member of the editorial board of the American Journal of Bioethics, as well as its conflict of interest committee.
	Gilead Sciences	Other	Individual	Under \$6,000	Current	Member of several data safety monitoring boards for Gilead Sciences studies.
	Janssen Pharmaceuticals	Advisory Board	Individual	\$6,000–\$20,000	Current	Member of a Pediatric Advisory Board to help develop appropriate strategies for evaluating new agents in children. No past disclosures reported.
Robert Pignolo	University of Pennsylvania					
Deborah Sellmeyer	Amgen	Other	Individual	\$0	Current	Member, Data Safety Monitoring Board.
	The Johns Hopkins Bayview Medical Center					

## Acknowledgments

Dr Nelson Watts served as a consultant to the Task Force and gave input on all Task Force documents. In addition, the authors thank international experts for their contributions to various parts of the manuscript: Dr Dennis Black for information, interpretation, and discussions regarding FLEX and HORIZON extension studies; Dr Felicia Cosman for discussions and information regarding the HORIZON study; Dr Richard Eastell for input regarding the usefulness of bone remodeling markers in the context of drug holidays; and the following experts for input regarding the developed algorithm and its applicability worldwide: Drs Peter Ebeling, Akira Itabashi, Aliya Khan, Edith Lau, William Leslie, Ambrish Mithal, and Michael McClung. The authors thank Drs Michael McClung and Marlene Chakhtoura for the Table summarizing approved osteoporosis therapies and antifracture efficacy by sex and skeletal site. The authors thank the following individuals at the American University of Beirut for their assistance in completing Task Force charges: Ms Aida Farha, medical information specialist, Saab Medical Library, for her advice and assistance in designing comprehensive and complex searches of the various medical literature resources and for the provision of select articles; Ms Maya Rahme for running the search and retrieving relevant articles; and Mr Ali Hammoudi for his artwork on the algorithm and Supplemental Appendices. The authors thank members of the ASBMR Professional Practice Committee (Suzanne Jan de Beur [Chair], Douglas Bauer, Jan Bruder, Nuria Guanabens, Eric Hesse, Erik Imel, Deborah Sellmeyer, Emily Stein, Pamela Taxel, and Bo Abrahamsen) for their insightful comments on the final draft of Task Force Report. Special thanks to Douglas Fesler and Kirsten Mills for their continued support throughout the work of the Task Force.

**Authors' roles:** The original charge came from the ASBMR Professional Practice Committee and was modified by the entire task force. All the drafts were written by the co-chairs with specific input from all of the members of the task force. The entire task force reviewed the manuscript, provided edits, and approved the final draft.

## References

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int*. 2006;17(12):1726–33.
2. Eisman JA, Bogoch ER, Dell R, et al. ASBMR Task Force on Secondary Fracture Prevention. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. *J Bone Miner Res*. 2012;27(10):2039–46.
3. FDA. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. 2011 [Accessed May 1, 2014]. Available from: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm270958.pdf>.
4. Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA*. 2006;296(24):2927–38.
5. Schwartz AV, Bauer DC, Cummings SR, et al. FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. *J Bone Miner Res*. 2010;25(5):976–82.
6. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. *Calcif Tissue Int*. 2004;75(6):462–8.
7. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res*. 2012;7(2):243–54.
8. Khosla S, Burr D, Cauley J, et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res*. 2007;22(10):1479–91.
9. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res*. 2014;29(1):1–23.
10. Shane E, Burr D, Ebeling PR, et al. American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res*. 2010;25(11):2267–97.
11. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. *J Bone Miner Res*. 2012;27(12):2544–50.
12. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. *N Engl J Med*. 2011;364(18):1728–37.
13. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. *N Engl J Med*. 2014;371(10):974–76.
14. FDA Drug Safety Communication. Ongoing safety review of oral bisphosphonates and atypical sub trochanteric femur fractures. 2011 [Accessed May 1, 2014]. Available from: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm>.
15. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis—where do we go from here? *N Engl J Med*. 2012;366(22):2048–51.
16. FDA panel: Rubin R. Osteoporosis drugs need better labels. Time limits on the drugs are suggested, but how much time is yet to be determined. 2011 [Accessed July 16, 2013]. Available from: <http://www.webmd.com/osteoporosis/news/20110909/fda-panel-unclear-on-osteoporosis-drug-labels>.
17. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res*. 2015;30(1):3–23.
18. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. *Mayo Clin Proc*. 2006;81(8):1013–22.
19. Russell RG. Bisphosphonates: the first 40 years. *Bone*. 2011;49(1):2–19.
20. Corona T, Rivera C, Otero E, Stopp L. A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's disease. *Clin Neuropharmacol*. 1995;18(4):325–32.
21. Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. *Curr Opin Rheumatol*. 2012;24(3):319–26.
22. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. *Endocr Pract*. 2010;16(6):1016–9.
23. Compston J, Bowring C, Cooper A, et al. National Osteoporosis Guideline Group. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. *Maturitas*. 2013;75(4):392–6.
24. American Society for Bone and Mineral Research. Ethics Policy and Guidelines for Leadership of the ASBMR [Accessed November 20, 2014]. Available from: <http://www.asbmr.org/About/PoliciesProcedures/Detail.aspx?cid=e407eef4-2166-4c8c-b75e-a42deb2ba99d>.



25. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. *Lancet*. 1996;348:1535–41.
26. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med*. 2007;356:1809–22.
27. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. *J Bone Miner Res*. 2004;19(8):1241–9.
28. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. *JAMA*. 1996;282(14):1344–52.
29. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. *N Engl J Med*. 1995;333(22):1437–43.
30. McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. *N Engl J Med*. 2001;344(5):333–40.
31. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. *Osteoporos Int*. 2000;11(1):83–91.
32. Miller PD, Recker RR, Harris S, et al. Long-term fracture rates seen with continued ibandronate treatment: pooled analyses of DIVA and MOBILE long-term extension studies. *Osteoporos Int*. 2014;25(1):349–57.
33. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. *JAMA*. 1998;280(24):2077–82.
34. McNabb BL, Vittinghoff E, Schwartz AV, et al. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. *J Bone Miner Res*. 2013;28(6):1319–27.
35. Garnero P, Hausherr E, Chapuy M, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. *J Bone Miner Res*. 1996;11(10):1531–8.
36. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. *J Clin Endocrinol Metab*. 2000;85:4118–24.
37. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. *J Bone Miner Res*. 2004;19(8):1259–69.
38. Ravn P, Christensen JO, Baumann M, Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. *Bone*. 1998;22(5):559–64.
39. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. *Osteoporos Int*. 2008;19(3):365–72.
40. Ebetino FH, Hogan AM, Sun S, et al. The relationship between the chemistry and biological activity of the bisphosphonates. *Bone*. 2011;49(1):20–33.
41. Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. *Bone*. 2006;38(5):628–36.
42. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. *Bone*. 2006;38(5):617–27.
43. Russel RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. *Osteoporos Int*. 2008;19(6):733–59.
44. Martin KE, Yu J, Campbell HE, Abarca J, White TJ. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates and all-cause cos. *J Manag Care Pharm*. 2011;17(8):596–609.
45. Akehurst R, Brereton N, Ariely R, et al. The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. *J Med Econ*. 2011;14(1):53–64.
46. Weycker D, Lamerato L, Schooley S, et al. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. *Osteoporos Int*. 2013;24(4):1483–9.
47. Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. *Osteoporos Int*. 2010;21(11):1943–51.
48. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. *Curr Med Res Opin*. 2006;22(7):1249–56.
49. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. *Osteoporos Int*. 2006;17(11):1638–44.
50. Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. *Endocr Pract*. 2006;12(5):522–8.
51. Jones TJ, Petrella RJ, Crilly R. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. *J Rheumatol*. 2008;35(9):1865–73.
52. Kamatari M, Koto S, Ozawa N, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. *J Bone Miner Metab*. 2007;25(5):302–9.
53. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. *Osteoporos Int*. 2006;17(6):922–8.
54. Sambrook PN, Cameron ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. *Osteoporos Int*. 2011;22(9):2551–6.
55. Curtis JR, Yun H, Matthews R, Saag KG, Delzell E. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. *Arthritis Care Res (Hoboken)*. 2012;64(7):1054–60.
56. Hadji P, Felsenberg D, Amling M, Hofbauer L, Kandenwein JA, Kurth A. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. *Osteoporos Int*. 2014;25(1):339–47.
57. Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. *JAMA Intern Med*. 2014;174(8):1263–70.
58. Cosman F, Cauley JA, Eastell R, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? *J Clin Endocrinol Metab*. 2014;99(12):4546–54.
59. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res*. 2015;30(5):934–44.
60. Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. *Osteoporos Int*. 2011;22(2):391–420.
61. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. *J Bone Miner Res*. 2004;19(8):1250–8.
62. Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB. Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. *J Bone Miner Res*. 2011;26(7):1662–9.

63. Delmas PD, Munoz F, Black DM, et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. *J Bone Miner Res.* 2009;24(9):1544–51.
64. Leslie WD, Lix LM. Comparison between various fracture risk assessment tools. *Osteoporos Int.* 2014;25(1):1–21.
65. Leslie WD, Majumdar S, Lix LM, et al. Can change in FRAX score be used to “treat-to-target”? A population-based cohort study. *J Bone Miner Res.* 2014;29(5):1074–80.
66. Leslie WD, Lix LM, Johansson H, et al. Does osteoporosis therapy invalidate FRAX for fracture prediction? *J Bone Miner Res.* 2012;27(6):1243–51.
67. Antonucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE. Vitamin D insufficiency does not affect response of bone mineral density to alendronate. *Osteoporos Int.* 2009;20(7):1259–66.
68. Cairoli E, Eller-Vainicher C, Olivieri FM, et al. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. *Osteoporos Int.* 2014;25(4):1401–10.
69. Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is  $\geq 33$  ng/ml. *Osteoporos Int.* 2012;23(10):2479–87.
70. Peris P, Torra M, Olivares V, et al. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. *Bone.* 2011;49(4):706–9.
71. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. *J Oral Maxillofac Surg.* 2009; 67(5 Suppl):2–12.
72. Tennis P, Rothman KJ, Bohn RL, et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. *Pharmacoepidemiol Drug Saf.* 2012;21(8):810–7.
73. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. *J Evid Based Dent Pract.* 2012;12(3 Suppl):233–47.
74. Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. *J Clin Endocrinol Metab.* 2014;99(8):2729–35.
75. Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. *J Am Dent Assoc.* 2011;142(11):1243–51.
76. Medication-Related Osteonecrosis of the Jaw–2014 Update–AAOMS Position Paper [Accessed June 24, 2014]. Available from: [http://www.aaoms.org/docs/position\\_papers/mronj\\_position\\_paper.pdf?pdf=MRONJ-Position-Paper](http://www.aaoms.org/docs/position_papers/mronj_position_paper.pdf?pdf=MRONJ-Position-Paper).
77. Denosumab (Xgeva<sup>®</sup>, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk. 2015 [Accessed July 25, 2015]. Available from: <https://www.gov.uk/drug-safety-update/denosumab-xgeva-prolia-intravenous-bisphosphonates-osteonecrosis-of-the-jaw-further-measures-to-minimise-risk>.
78. Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. *Int J Oral Maxillofac Surg.* 2015;44(5):568–85.
79. Edwards BJ, Bunta AD, Lane J, et al. Bisphosphonates and nonhealing femoral fractures: analyses of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events and Reports (RADAR) project. *J Bone Joint Surg Am.* 2013;95(4): 297–307.
80. Hagen JE, Miller AN, Ott SM, et al. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. *J Bone Joint Surg Am.* 2014;96(22):1905–9.
81. Oh Y, Wakabayashi Y, Kurosa Y, Fujita K, Okawa A. Potential pathogenic mechanism for stress fractures of the bowed femoral shaft in the elderly: mechanical analyses by the CT-based finite element method. *Injury.* 2014;45(11):1764–71.
82. Paparodis R, Buehring B, Pelley EM, Binkley N. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. *Endocr Pract.* 2013;19(3): e64–8.
83. Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab—a case report. *Acta Orthop.* 2014;85(1):6–7.
84. Schneider JP, Hinshaw WB, Su C, Solow P. Atypical femur fractures: 81 individual personal histories. *J Clin Endocrinol Metab.* 2012; 97(12):4324–8.
85. Khoo KS, Yong TY. Atypical femoral fracture in a patient treated with denosumab. *J Bone Miner Metab.* 2015;33(3):355–8.
86. Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. *Rheumatology (Oxford).* 2014;53(1):19–31.
87. Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. *J Bone Miner Res.* 2013;28(10):2049–59.
88. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. *Osteoporos Int.* 2011;22(12):2951–61.
89. Van der Meulen MC, Boskey AL. Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality. *Arthritis Res Ther.* 2012;14(4):220.
90. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. *J Clin Endocrinol Metab.* 2005;90(3): 1294–301.
91. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. *J Clin Endocrinol Metab.* 2008;93(8):2948–52.
92. Cauley JA, Chalhoub D, Kassem AM, Fuleihan Gel-H. Geographic and ethnic disparities in osteoporotic fractures. *Nat Rev Endocrinol.* 2014;10(6):338–51.
93. Cauley JA, Wampler NS, Barnhart JM, et al. Incidence of fractures compared to cardiovascular disease and breast cancer: the Women’s Health Initiative Observational Study. *Osteoporos Int.* 2008;19(12):1717–23.
94. Center for Disease Control. Pedestrian safety: fact sheet. 2013 [Accessed May 1, 2014]. Available from: [http://www.cdc.gov/motorvehiclesafety/pedestrian\\_safety/factsheet.html](http://www.cdc.gov/motorvehiclesafety/pedestrian_safety/factsheet.html).
95. Center for Disease Control. Homicide rates among persons aged 10–24—United States, 1981–2010. 2013 [Accessed May 1, 2014]. Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6227a1.htm>.
96. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet.* 2009;373(9678):1849–60.
97. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. *J Clin Endocrinol Metab.* 2011;96(9):2675–80.
98. Lampropoulou-Adamidou K, Tournis S, Balanika A, et al. Sequential treatment with teriparatide and strontium ranelate in a postmenopausal woman with atypical femoral fractures after long-term bisphosphonate administration. *Hormones.* 2013;12(4):591–7.
99. Miyakoshi N, Aizawa T, Sasaki S, et al. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. *J Bone Miner Metab.* 2014;10(6):338–51.
100. Crandall CJ, Newberry SJ, Diamant A, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. *Ann Intern Med.* 2014;161(10): 711–23.
101. Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. *J Clin Endocrinol Metab.* 2012;97(6):1871–80.
102. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. *J Bone Miner Res.* 2010;25(1):72–81.

103. Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. *Bone*. 2014;58(1):48–54.
104. Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. *Obstet Gynecol*. 2013;121(6):1291–9.
105. Amgen. Safety and efficacy study to evaluate denosumab compared with zoledronic acid in postmenopausal women with osteoporosis. 2015 [Accessed May 1, 2015]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01732770>. NLM Identifier: NCT01732770.
106. Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. *J Bone Miner Res*. 2014;25(7):1953–61.
107. Vestergaard P, Fischer L, Mele M, Mosekilde L, Christiansen P. Use of bisphosphonates and risk of breast cancer. *Calcif Tissue Int*. 2011;88(4):255–62.
108. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study. *Osteoporos Int*. 2012;23(11):2693–701.
109. Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R. Esophageal and gastric cancer incidence and mortality in alendronate users. *J Bone Miner Res*. 2012;27(3):679–86.
110. Hue TF, Cummings SR, Cauley JA, et al. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. *JAMA Intern Med*. 2014;174(10):1550–7.
111. Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analyses of the Austrian Breast and Colorectal Cancer Study Group Trial 12. *Ann Oncol*. 2015;26(2):313–20.
112. Kang JH, Keller JJ, Lin HC. A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. *Osteoporos Int*. 2012;23(10):2551–7.
113. Pittman CB, Davis LA, Zeringue AL, et al. Myocardial infarction risk among patients with fractures receiving bisphosphonates. *Mayo Clin Proc*. 2014;89(1):43–51.
114. Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. *Osteoporos Int*. 2011;22(3):983–91.
115. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. *J Clin Endocrinol Metab*. 2010;95(3):1174–81.
116. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. *J Clin Endocrinol Metab*. 2011;96(4):1006–14.
117. Hartle JE, Tang X, Kirchner HL, et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. *Am J Kidney Dis*. 2012;59(5):636–44.
118. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med*. 2007;357(18):1799–809.
119. Perkins RM, Kirchner HL, Matsushita K, Bucaloiu ID, Norfolk E, Hartle JE. Bisphosphonates and mortality in women with CKD and the presence or absence of cardiovascular disease. *Clin J Am Soc Nephrol*. 2014;9(4):706–9.
120. Colón-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. *J Bone Miner Res*. 2010;25(1):91–7.
121. Giangregorio LM, Leslie WD, Program MBD. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. *J Bone Miner Res*. 2010;25(6):1400–5.
122. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. *JAMA*. 2001;285(3):320–3.
123. Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P. Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169, 145 cases during 1977–2001. *J Bone Miner Res*. 2009;24(7):1299–307.
124. Schousboe JT, Fink HA, Lui LY, Taylor BC, Ensrud KE. Association between prior non-spine non-hip fractures or prevalent radiographic vertebral deformities known to be at least 10 years old and incident hip fracture. *J Bone Miner Res*. 2006;21(10):1557–64.
125. van Geel TA, Huntjens KM, van den Bergh JP, Dinant GJ, Geusens PP. Timing of subsequent fractures after an initial fracture. *Curr Osteoporos Rep*. 2010;8(3):118–22.
126. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. *J Bone Miner Res*. 2014;19(6):893–9.
127. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Care Res (Hoboken)*. 2010;62(11):1515–26.
128. Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int*. 2012;23(9):2257–76.
129. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. *N Engl J Med*. 1997;337:382–7.
130. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet*. 2009;373(9671):1253–63.
131. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. *European Corticosteroid-Induced Osteoporosis Treatment Study*. *J Bone Miner Res*. 2000;15(6):1006–13.
132. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. *Glucocorticoid-Induced Osteoporosis Intervention Study Group*. *N Engl J Med*. 1998;339(5):292–9.
133. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med*. 2007;357(20):2028–39.
134. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. *Arthritis Rheum*. 2009;60(11):3346–55.
135. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. *Calcif Tissue Int*. 2000;67(4):277–85.
136. Van Staa TP, Leuffkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int*. 2002;13(10):777–87.
137. Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. *Bone*. 2012;51(3):383–8.
138. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. *J Bone Miner Res*. 2009;24(4):719–25.
139. FDA Product Information. Reclast (R) intravenous injection, zoledronic acid intravenous injection. Novartis Pharmaceuticals Corporation (per FDA). East Hanover, NJ, 2013.
140. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. *N Engl J Med*. 2000;343(9):604–10.
141. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a

- prospective, comparative, two-arm study. *Rheumatol Int.* 2004; 24(2):110–3.
142. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. *Rheumatol Int.* 2006;26(5):427–31.
143. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. *N Engl J Med.* 2012;367(18):1714–23.
144. Safford MM, Barasch A, Curtis JR, Outman R, Saag K. Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration. *J Clin Rheumatol.* 2014;20(7):357–62.
145. Ensrud KE, Taylor BC, Peters KW, et al. Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analyses of prospective cohort study. *BMJ.* 2014;Jul 3(349):g4120.
146. Uhlig K, Leff B, Kent D, et al. A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity. *J Gen Intern Med.* 2014;29(4): 670–9.